Navigation Links
SemBioSys Presents Positive Insulin Data at the American Diabetes,Association Conference

- Canadian Biotechnology Company updates progress and upcoming milestones on its insulin program -

CALGARY, June 26, 2007 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. , a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular disease, today announced positive preclinical data supporting the development of plant-derived recombinant human insulin. The Company presented its findings at the 67th Scientific Sessions of the American Diabetes Association (ADA) in Chicago. Specifically, the Company's abstract and poster presentation highlighted its recent accomplishments in the development of a highly-scalable, low-cost source of insulin, including:

    -  Results demonstrating that the Company exceeded its commercial target

       levels of insulin accumulation in safflower, its commercial plant


    -  Laboratory results demonstrating that safflower-produced insulin is

       physically, structurally and physiologically indistinguishable from

       pharmaceutical-grade human recombinant insulin.

    -  Laboratory results from competitive receptor binding assays

       demonstrating the functional equivalence of the Company's

       safflower-produced insulin to insulin reference standard.

    -  Animal results from insulin tolerance test assays demonstrating the

       pharmacodynamic equivalence of safflower-derived insulin to

       pharmaceutical-grade insulin.

"These results validate the feasibility of our plant production technology for the large-scale manufacture of human insulin. Plants are a transformative platform for the production of biopharmaceuticals. They are ideally suited to large volume products such as human insulin, where capacity is in short supply. Plants offer unprecedented capacity and flexibility for low-cost biopharmaceutical manufacturing and provide by far the most attractive economics, both in terms of capital and cost of goods," said Andrew Baum, President and CEO of SemBioSys Genetics Inc. "We have confirmed our intention to pursue an abbreviated clinical trial under the 505(b)(2) rules of the Food and Drug Act after a meeting with the U.S. Food and Drug Administration late last year. We expect to enter directly into a Phase II trial in early 2008 with commercialization of safflower-produced insulin scheduled for as early as 2010."

During the Scientific Sessions on Sunday June 24th, Dr. Larry C. Deeb, ADA President, Medicine and Science, highlighted the need for increased access to insulin and insulin treatment as part of his presidential address. Dr. Deeb described the dire situation facing those suffering from type 1 diabetes in parts of Africa where the cost of insulin is a primary barrier to treatment.

Insulin is the largest volume recombinant biopharmaceutical product on the market today with production estimated at approximately 6,000 kilograms in 2006 and sales in excess of US$7.5 billion worldwide. SemBioSys estimates that the demand for insulin will increase to nearly 16,000 kilograms in 2012; fuelled by an increasing incidence of diabetes, increasing demand for access to insulin treatment in the developing world and adoption of alternate insulin delivery technologies, which require between 5 to 20 times more insulin than injection methods, in the developed world.

The scientific poster and abstract SemBioSys presented at the ADA were entitled: "Chemical and Biological Characterization of Recombinant Human Insulin Produced in Transgenic Plants." Abstract Number 0459-P by Joseph Boothe and colleagues at SemBioSys.

About SemBioSys Genetics Inc. (

Calgary, Alberta-based SemBioSys Genetics Inc. is a biotechnology company developing insulin and other protein-based pharmaceuticals for metabolic and cardiovascular diseases. The Company's lead candidate is recombinant human insulin produced in the plant host safflower, to serve the rapidly expanding global diabetes market and to supply insulin for inhalation and other alternative insulin delivery technologies. The Company's other protein-based pharmaceutical candidate is a cardiovascular drug called Apo AI. SemBioSys is also developing a series of non-pharmaceutical products addressing animal and aquaculture health, nutritional oils and human topical markets.

This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time-to-time in the Company's ongoing filings with the Canadian securities regulatory authorities which filings can be found at Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable Canadian securities laws.

CONTACT: SemB ioSys Genetics Inc., Mr. Andrew Baum, President and ChiefExecutive Officer, Phone: (403) 717-8767, Fax: (403) 250-3886, E-mail:, Internet:; Investor Relations, RossMarshall, The Equicom Group Inc., Phone: (416) 815-0700 (Ext. 238), Fax:(416) 815-0080, E-mail:

Ticker Symbol: (Toronto:SBS.)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


Related medicine technology :

1. SemBioSys to present new data at American Diabetes Association annual meeting
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
11. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
Post Your Comments:
(Date:11/30/2015)... -- IBA Molecular North America, Inc. (IBAMNA), a U.S. leader ... as of January 1, 2016, it will do business ... rebrand the company reflects a refined vision for the ... relationship with Zevacor Molecular.  Both IBAMNA and Zevacor Molecular ... Peter Burke , Vice President Sales and ...
(Date:11/30/2015)... -- North America was valued at ... a CAGR of 7.6% from 2015 to 2020. --> ... in 2014, and is expected to grow at a CAGR of ... new Market Research Report "North America Cardiac Output Monitoring Devices Market ... care, others) - Analysis And Forecast To 2020", the cardiac output ...
(Date:11/30/2015)... 30, 2015  Kevin Smith has been appointed ... global pioneer in wireless monitoring of vital signs.  ... , Mr. Smith will be responsible for ... strategy.  He will also directly oversee partnering with ... evidence for SensiumVitals, the first early warning detection ...
Breaking Medicine Technology:
(Date:11/30/2015)... , ... November 30, 2015 , ... ... Beard and Brooke Bennett are collaborating with brands across various categories through traditional ... influential figures make up an elite group of Gold Medal Moms who can ...
(Date:11/30/2015)... Garden City, NY (PRWEB) , ... December 01, 2015 , ... ... as a 2015-2016 inductee into its VIP Woman of the Year Circle. She ... is the nation’s leading networking organization exclusively for professional women, boasting more than 850,000 ...
(Date:11/30/2015)... ... 2015 , ... Being a caregiver for someone you love ... Care System, the Caregiver Support Program promotes the health and wellbeing of family ... percent report that their role as a caregiver has created marital strain,” said ...
(Date:11/30/2015)... ... November 30, 2015 , ... According to research by ... require dental technicians to be certified or obtain continuing education. To increase awareness ... In Your Mouth?” campaign to inform dentists that the technicians they trust could ...
(Date:11/30/2015)... ... November 30, 2015 , ... The Museum of Science & ... a new era of publicly accessible automated technology. Now, by popular demand, the ... guests an up-close look at the shuttle at MOSI’s main entrance. This experience ...
Breaking Medicine News(10 mins):